Polyrizon Ltd Stock Price, News & Analysis

Polyrizon (NASDAQ: PLRZ) has initiated preclinical studies for intranasal Benzodiazepines (BZDs) using its proprietary Trap and Target™ (T&T) platform for treating acute repetitive seizures and status epilepticus. The studies, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, will evaluate drug loading capacity, release kinetics, nasal deposition, and stability.

The global acute repetitive seizures market, valued at $3.15 billion in 2024, is projected to grow at a 12.7% CAGR from 2025-2030. Additionally, the epilepsy treatment devices market is expected to reach $787.3 Million by 2033, growing at a 4.1% CAGR.

The initiative aims to develop a faster, safer, and more accessible solution for managing acute seizures outside clinical settings, targeting the approximately 50 million people worldwide affected by epilepsy according to WHO data.

Polyrizon (Nasdaq: PLRZ) has signed a non-binding Letter of Intent (LOI) with an unnamed biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatments. The collaboration will leverage Polyrizon's proprietary intranasal hydrogel platform to optimize drug delivery.

Under the LOI terms, Polyrizon will lead the formulation development using its mucoadhesive drug delivery technology, while the psychedelic company will fund research and development, including feasibility studies. Upon successful proof of concept, the parties plan to negotiate a definitive agreement covering IP ownership, commercialization rights, and financial terms, with Polyrizon receiving royalties on future product commercialization.

Polyrizon (Nasdaq: PLRZ) has initiated preclinical studies for intranasal Naloxone using their proprietary Trap and Target™ (T&T) platform. The studies, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, will evaluate key parameters including drug loading capacity, release kinetics, nasal deposition, and stability.

The company aims to enhance intranasal Naloxone delivery to combat the global opioid crisis by potentially offering higher bioavailability and optimized drug release profiles. This development targets the growing Naloxone market, projected to reach $2.47 billion by 2032 with an 11% CAGR, where the intranasal spray segment alone is expected to reach $1.4 billion by 2030.

Intranasal delivery offers several advantages including easier administration, no need for trained medical personnel, reduced needlestick injury risks, and increased accessibility for emergency responders and at-risk individuals.

Polyrizon (Nasdaq: PLRZ), a development stage biotech company focused on innovative intranasal hydrogels, has announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC).

The report is accessible through the SEC's website and Polyrizon's Investor Relations website. Shareholders can request free copies of the annual report by contacting the company's Investor Relations Department.

Polyrizon (Nasdaq: PLRZ) has initiated preclinical studies for intranasal Naloxone, targeting opioid overdose treatment using its proprietary Trap and Target™ (T&T) platform. The study will be conducted in collaboration with Professor Fabio Sonvico from the University of Parma, focusing on key parameters like drug loading capacity, release kinetics, nasal deposition, and stability.

The company aims to enhance intranasal Naloxone delivery by improving bioavailability and optimizing drug release profiles for rapid opioid reversal in emergency situations. This development addresses the ongoing global opioid crisis, particularly driven by fentanyl and synthetic opioids.

Market projections indicate significant growth potential:

• Global Naloxone market expected to reach $2.47 billion by 2032 (11% CAGR)
• Naloxone intranasal spray market projected to hit $1.4 billion by 2030

Polyrizon (PLRZ) has filed a divisional patent application in Israel for its Trap & Target (T&T) platform technology, focusing on advanced intranasal drug delivery systems. This follows their recent U.S. patent application covering both T&T and Capture and Contain (C&C) platforms.

The T&T platform aims to enhance medication effectiveness through improved nasal residence time and mucosal contact. Key features include prolonged residence time, improved bioavailability, controlled release, drip prevention, biodegradable components, and compatibility with various drug types including small molecules, proteins, peptides, and antibodies.

The technology leverages nasal cavity vascularization for both local and systemic drug delivery, targeting applications such as corticosteroids for allergic rhinitis, benzodiazepines for epileptic seizures, and naloxone for opioid overdose.

Polyrizon has initiated preliminary Good Manufacturing Practice (GMP) manufacturing process for its PL-14 allergy blocker in preparation for planned 2025 clinical trials. The company has partnered with Eurofins CDMO Amatsiaquitaine S.A.S. as their GMP manufacturer to support future commercialization efforts.

The designated manufacturing facility is equipped to meet clinical trial material requirements, ensuring high-quality production and regulatory compliance. The upcoming trial will evaluate PL-14's safety and efficacy as an innovative allergy blocker, delivered through proprietary nasal spray solutions.

According to CEO Tomer Izraeli, the global nasal spray market is projected to exceed $23 billion by 2029. The company aims to address growing market demand with their novel intranasal solution, which they believe could enhance current allergy treatment options.

Polyrizon (PLRZ) has announced the publication of a national phase patent application by the USPTO for its intranasal hydrogel technologies. The patent application covers two core platforms: Capture and Contain (C&C™) and Trap and Target (T&T™).

The C&C™ platform features a natural 3D polymeric network that adheres to nasal mucosa, creating a physical barrier against airborne biological threats like allergens, viruses, and molds. The T&T™ platform is designed for enhanced drug delivery, offering prolonged residence time and close mucosal contact for improved therapeutic efficacy. The technology can be customized for various molecules and medical applications.

Polyrizon (Nasdaq: PLRZ) has appointed Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs. This strategic appointment comes as the company prepares for its PL-14 clinical trial, scheduled to begin in 2025. Dr. Meir, currently a Senior Consultant at MedTech SME , brings over a decade of experience in medical device and pharmaceutical industries. Her expertise spans regulatory strategy, clinical affairs management, and product development, with previous leadership roles at Medtech SME , Keystone Heart, and Alma Lasers. The appointment aligns with Polyrizon's focus on developing innovative intranasal hydrogels and strengthening its regulatory compliance and clinical excellence capabilities.